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Open acObjective: Single-ventricle patients undergoing pediatric heart surgery are a high-risk group owing to
reoxygenation injury during cardiopulmonary bypass (CPB). The present study investigated the effects of
controlled reoxygenation CPB on biomarkers of organ damage, inflammation, stress, and long-term functional
outcomes in cyanotic patients with either a single or double ventricle during open heart surgery.
Methods: Cyanotic patients with either a single (n ¼ 32) or double (n ¼ 47) ventricle undergoing surgical
correction were randomized to receive CPB using either standard oxygen levels or controlled reoxygenation.
The markers of cardiac injury, inflammation, stress, and cerebral and hepatic injury were measured
preoperatively, at 10 and 30 minutes after starting CPB, and at 10 minutes and 4 and 24 hours after CPB.
The data were analyzed using a mixed regression model.
Results: No difference was found in the pre- or intraoperative characteristics between the standard and
controlled reoxygenation CPB groups for single- or double-ventricle patients. In the single-ventricle patients,
controlled reoxygenation CPB significantly (P<.05) decreased the markers of organ damage, inflammation,
stress, and oxidative stress. In contrast, the markers of inflammation and cardiac injury were not altered by
controlled reoxygenation CPB in the double-ventricle patients.
Conclusions: Controlled reoxygenation CPB decreased the markers of organ damage, stress, inflammation, and
oxidative stress in single-ventricle patients undergoing cardiac surgery. (J Thorac Cardiovasc Surg
2014;148:792-801)Supplemental material is available online.
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cess under CC BY-NC-ND license.(eg, hypoplastic left heart syndrome, tricuspid atresia, and
double-inlet left ventricle), children with these malforma-
tions are exposed to very similar pathophysiologic states.
The functional single-ventricle palliation often includes 3
operations. The first stage of palliation is performed at birth.
The second stage is a bidirectional Glenn operation, usually
undertaken at 6 to 8 months of age. The third, and final,
stage is the Fontan operation, which can be performed
between 18 months and 4 years of age. These infants and
children are at a very high risk of developing perioperative
and long-term complications that could affect their quality
of life.1,2 Additionally, a single ventricle has been
considered a risk factor for operative mortality,3 although
this remains debatable.4
Reintroduction of high oxygen levels to cyanotic patients
when starting cardiopulmonary bypass (CPB) leads to
reoxygenation injury with significant organ damage,
including the myocardium and triggering of a systemic
inflammatory response.5-7 One of the strategies proposed
to avoid reoxygenation injury has been the use of
controlled reoxygenation using a partial pressure of
oxygen in arterial blood (PaO2) similar to the patient’s
preoperative oxygen saturation when starting CPB.
This has been shown to ameliorate reoxygenation injury
in experimental models,8,9 in adult patients,10 and,
more recently, in cyanotic pediatric patients with mixedery c September 2014
Abbreviations and Acronyms
C3a ¼ complement activation
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
IL ¼ interleukin
MIF ¼ microphage migration inhibitor factor
PaO2 ¼ partial pressure of oxygen in arterial blood
TnI ¼ troponin I
Caputo et al Congenital Heart Disease
C
H
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However, the degree and nature of cyanosis will vary
depending on the individual pathologic features, with no
studies comparing the efficacy of this intervention in
cyanotic patients with different pathologic features and
different risk stratification. Of particular interest are
patients with a single ventricle who are at a greater risk of
developing reoxygenation injury and its deleterious
effects on multiple organ function. These patients have
chronic cyanosis and have a relatively short cardioplegic
arrest; thus, it has been easier to identify CPB-induced
reoxygenation as the main culprit triggering organ injury
and systemic stress. In the present study, we investigated
whether controlled reoxygenation when starting CPB
would alter the markers of organ damage, stress, inflamma-
tion, and oxidative stress in cyanotic patients with a single
or double ventricle when undergoing cardiac surgery.
METHODS
The patients in the present study were a part of a large trial (study no.
CS/2007/2678, recruitment just completed) investigating the effect of
controlled reoxygenation CPB in cyanotic children undergoing surgical
correction at the Bristol Royal Hospital for Children. The patients were
randomized to receive CPB with either a standard oxygen partial pressure
(150-200 mm Hg, hyperoxic to patients) or controlled oxygen partial pres-
sure (matched to patients, normoxic). Data from a group of patients in the
initial phase of recruitment have been published without any reference to
the specific pathologic features or clinical outcomes.11 The present study
was a subanalysis of the effect of controlled reoxygenation in patients
(including those from the first report) with either single (n¼ 32) or double
(n ¼ 47) ventricular pathologic features and included long-term clinical
data (eg, cardiac function, New York Heart Association, and survival).
All patients were in a stable condition without preoperative respiratory
or inotropic support. Standard CPB referred to a pump prime prepared to
the current ‘‘best practice’’ protocols, which has an oxygen partial pressure
that is relatively hyperoxic for a cyanotic patient. The hospital research
ethics committee approved the present study, and parental informed
consent was obtained for all patients. Treatment allocations, stratified by
age (<6 months vs 6 months), were generated by computer in advance
of starting the study, using block randomization with varying block sizes.
The surgical team, with the exception of the perfusionists, were unaware
of the treatment allocation. The preoperative characteristics of the 2 groups
for the single- and double-ventricle patients are summarized in Table 1 and
Table E1.
All operations were performed with CPB. The intraoperative anesthetic
and operative techniques were standardized as previously reported.12 Cold
blood (4C-6C) St Thomas’ no. I-based blood cardioplegic solution
(4:1 dilution blood/St Thomas’ no. I crystalloid cardioplegia) was usedThe Journal of Thoracic and Cafor myocardial preservation, with the following composition: 16 mM
MgCl2, 2 mM CaCl2, 20 mM KCl, 147 mM NaCl, and 1.0 mM procaine
HCl. Additional cardioplegia was administered after each 20 minutes of
aortic crossclamping. Postoperatively, all the patients were admitted to
the pediatric intensive care unit and were treated according to the unit
protocols12,13 by intensivists and pediatric cardiologists who were
unaware of the treatment allocation.CPB and Control of Oxygen Partial Pressure
The reoxygenation strategy when starting CPB was developed in our
clinical perfusion science department.
Controlled reoxygenation CPB. The CPB circuit was set up
and primed in accordance with the protocol,5,13 usually with a red
blood cell/albumin prime solution or, occasionally, a clear prime
solution, depending on the patient’s hemoglobin level. Just before the
initiation of CPB, medical nitrogen was delivered to the gas exchange
device (oxygenator) by way of a bacteriologic filter (0.2 mm) at a rate of
100 to 200 mL/min, and the prime was circulated at approximately
1000 mL/min. An in-line PaO2 monitor was used to measure the PaO2 of
the prime. Using this technique, we were able to reduce the PaO2 of the
prime fluid to match that of the patient’s own PaO2 levels. Finally,
before CPB was established, the prime PaO2 was confirmed using a
point-of-care blood gas analyzer, and the in-line PaO2 monitor was
calibrated. CPB was initiated in this relatively ‘‘normoxic’’ manner, and
the PaO2 levels of the arterialized blood were adjusted accordingly during
CPB (Table 1).
Standard (hyperoxic) CPB group. Oxygen delivery was run at
100% to maintain the arterial oxygen saturation at>95% and PaO2 levels
of 150 to 200 mm Hg when starting CPB (Table 1 and Table E1).Biomarkers of Organ Injury and Stress
The primary endpoints were the release of troponin I (TnI)
(enzyme-linked immunosorbent assay; Access Immunoassay System,
Beckman Instruments Inc, Fullerton, Calif) and 8-isoprostane (enzyme
immunoassay; Cayman Chemicals, Ann Arbor, Mich) as measurements
of myocardial cell damage and oxidative stress, and the release of markers
of the whole body inflammatory response, including complement
activation (C3a; BD OptEIA Human C3a ELISA; BD Biosciences,
Franklin Lakes, NJ), interleukin (IL)-6, IL-8, IL-10, and microphage
migration inhibitor factor (MIF) (enzyme-linked immunosorbent assay;
Amersham Biosciences UK, Little Chalfont, United Kingdom), and stress
response (cortisol; Access Immunoassay System, Beckman Coulter,
Pasadena, Calif). Cerebral injury was assessed by the postoperative release
of protein S100 (CanAg S100 EIA; CanAg Diagnostics AB, Goteborg,
Sweden), and a-glutathione S-transferase (Biotrin High Sensitivity Alpha
GST EIA Assay; Biotrin International, Dublin, Ireland) was used to assess
hepatic cell damage.
Blood (2-3 mL) was collected preoperatively, at 10 and 30 minutes
after starting CPB, and at 10 minutes and 4 and 24 hours after the
cessation of CPB. This was immediately centrifuged at 4C, at 4000 rpm
for 15 minutes. The resulting plasma was then frozen in liquid nitrogen
before storage at 80C. A laboratory technician, who was unaware of
the treatment allocation and clinical status of the patient, performed the
assays.
The clinical outcomes (inotropic support, renal failure, intubation time,
postoperative hospital stay, New York Heart Association class, and survival
at follow-up) were also recorded. Myocardial function was assessed
preoperatively, immediately postoperatively, and during follow-up for
patients with a single ventricle using commercially available instruments
(Vivid 7 imaging device, GE Healthcare, Little Chalfont, United Kingdom).
All echocardiographic and Doppler data were obtained in digital format and
stored on a workstation for offline analysis (EchoPAC; GE Vingmed
Ultrasound AS, Horten, Norway). Ventricular function was defined asrdiovascular Surgery c Volume 148, Number 3 793
TABLE 1. Preoperative characteristics, intra- and postoperative data in single-ventricle patients exposed to standard or controlled reoxygenation
Variable Standard (hyperoxic) (n ¼ 16) Controlled reoxygenation (n ¼ 16) P value
Age (mo) 135 (55-206) 123 (68.3-169) .5
Male sex 9 (57) 10 (62) .7
Weight (kg) 16.1 (11.6-19.6) 13.9 (10.6-19.6) .7
Preoperative saturation (%) 77.7  7.1 81.0  7.5 .2
Pathologic entity .2
Pulmonary atresia 5 (31) 11 (69)
Tricuspid atresia 7 (44) 2 (13)
Double inlet left ventricle 2 (13) 1 (6)
Ebstein anomaly 2 (13) 1 (6)
Mitral stenosis 0 1 (6)
Operation .4
Glenn shunt 8 (50) 7 (44)
TCPC 8 (50) 9 (56)
PaO2
At start of CPB 167.8  70.2 55.4  13.7 <.001
At 5 min of CPB 169.6  61.5 63.7  20.5 <.001
At 10 min of CPB 171.8  55.9 65.8  18.2 <.001
At 30 min of CPB 155.6  39.0 114.4  29.7 .001
Immediately after CPB 173.2  56.2 159.4  41.1 .4
CPB time (min) 72.2 (43-136) 67.2 (34-178) .9
Crossclamp time (min) 6.1  14.1 11.6  21.9 .4
30-d mortality 0 0
Ventilation time (min) 11.5 (2-33) 21.2 (2-188) .4
Dopamine support off CPB (mg/kg/min) 6.1  4.7 5.3  5.3 .6
Dopamine support at peak dose (mg/kg/min) 10.3  6.3 9.8  5.3 .8
Dopamine support duration (h) 62.6  61.6 40.3  62.8 .5
Length of hospital stay (d) 20.5 (7.7-28.5) 13.0 (6.0-17.0) .7
Data presented as median (interquartile range), n (%), or mean standard deviation. TCPC, Total cavopulmonary connection; PaO2, partial pressure of oxygen in arterial blood;
CPB, cardiopulmonary bypass.
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(ejection fraction<50% but>30%), or severely impaired (ejection fraction
<30%).14
Sample Size
The sample size was calculated from the results of previous similar
studies performed at our institution.11,12 With 1 preoperative and 5
postoperative measurements, a sample size of 15 to 20 per group would
have>90% power to detect effect sizes of 0.5 for both markers at the
5% statistical significance level (2-tailed), assuming a correlation of
0.7 between the preoperative and postoperative values and among the
postoperative measures.
Statistical Analysis
Continuous outcomes are expressed as the mean standard deviation if
normally distributed or the geometric mean or median and interquartile
range if skewed. Categorical data are presented as actual counts and
percentages. Skewed measures were log-transformed to achieve normality,
and the results were back transformed to the original scale. Biochemical
markers measured at multiple points were analyzed using a mixed
regression model. All the markers had a skewed distribution and were
analyzed on the logarithmic scale. These analyses were adjusted for age,
baseline response, pathologic findings, and the interaction between the
pathologic entity and time and the treatment and time. An overall estimate,
pooled over all measurement points, is reported. Effect sizes are reported as
the mean differences (if normally distributed) or as ratios of geometric
means (if skewed), with corresponding 95% confidence intervals (CIs)
and P values. Survival was evaluated using the Kaplan-Meier method,
and the log-rank test was used to compare the 2 groups.794 The Journal of Thoracic and Cardiovascular SurgRESULTS
The intraoperative and clinical outcomes for the single-
and double-ventricle patients are listed in Table 1 and
Table E1. No deaths occurred in this series 30 days
postoperatively. Overall, no significant differences were
found in terms of the perioperative clinical outcomes
between the controlled reoxygenation CPB and standard
(hyperoxic) CPB groups in either the single- or double-
ventricle patients.
Two patients in the standard (hyperoxic) CPB group who
underwent total cavopulmonary connection died within 1
year postoperatively of cardiac-related causes and 1 patient
in the same group died 2 years after a Glenn procedure of
bowel perforation and peritonitis. At a median follow-up
of 7 years for patients with a single ventricle, survival was
100% in the controlled reoxygenation CPB group and
81% in the standard (hyperoxic) CPB group (P ¼ .03;
Figure E1). The double-ventricle patients had 100%
survival with or without either intervention. Overall, more
patients in the standard (hyperoxic) CPB group were in
New York Heart Association class II and III (Figure 1, A)
compared with the controlled reoxygenation CPB
group (55.6% vs 22.5%). This difference was more
prominent for single-ventricle patients (76.9% vs 23.1%ery c September 2014
FIGURE 1. NewYork Heart Association (NYHA) class at follow-up (mean, 7 years) in (A) all patients or (B) patients with a single ventricle in the standard
(hyperoxic) and controlled reoxygenation groups.
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tively; Figure 1, B).
The preoperative and long-term (7 years) cardiac
function classifications for patients with a single ventricle
are shown in Figure 2.
Markers of Inflammation, Stress, and Organ Injury
in Single-Ventricle Patients
Controlled reoxygenation CPB significantly decreased
the inflammatory and stress response compared with
standard (hyperoxic) CPB in patients undergoing single
ventricle surgical correction (Figure 3). Furthermore, the
overall release of ILs (IL-6, IL-8, IL10), C3a, MIF, and
cortisol was significantly reduced by controlling the oxygen
levels when starting CPB (Table E2).
At 10 minutes after starting CPB, the TnI levels
were significantly greater than baseline in both groupsThe Journal of Thoracic and Ca(Figure 4, Table E2). The levels had peaked at 4 hours after
surgery and remained high (compared with baseline) at
24 hours. Overall, the TnI levels were significantly
lower in the controlled reoxygenation CPB group than in
the standard (hyperoxic) CPB group (ratio, 0.58; 95% CI,
0.51-0.65; P<.01).
Controlled reoxygenation CPB significantly decreased
the postoperative 8-isoprostane release compared with
standard (hyperoxic) CPB (ratio, 0.76; 95% CI, 0.65-0.91;
P ¼ .002).
In both groups, an increase in serum protein S100
occurred soon (10 minutes) after the initiation of CPB and
peaked at 10 minutes after withdrawing CPB. The release
of protein S100 was significantly lower in the controlled
reoxygenation CPB group than in the standard (hyperoxic)
CPB group (ratio, 0.78; 95% CI, 0.66-0.91; P ¼ .002;
Figure 4, Table E2).rdiovascular Surgery c Volume 148, Number 3 795
FIGURE 2. Cardiac function classification in single-ventricle patients in the standard (hyperoxic) and controlled reoxygenation groups. The change in
classification between the preoperative and long-term outcomes was significantly (P<.01, Mann-Whitney U test for unpaired comparison) improved
with controlled reoxygenation compared with standard (hyperoxic) reoxygenation.
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hours after termination of CPB. Overall, a significant
reduction occurred in serum a-glutathione S-transferase
release in the controlled reoxygenation CPB group
compared with that in the standard (hyperoxic) CPB
group (ratio, 0.71; 95% CI, 0.60-0.85; P<.01; Figure 4,
Table E2).
Markers of Inflammation, Stress, and Organ Injury
in Double-Ventricle Patients
In patients with double ventricular anatomy undergoing
surgical correction, controlling reoxygenation did not
seem to significantly decrease the postoperative release of796 The Journal of Thoracic and Cardiovascular SurgIL-6, IL-8, C3a, and MIF. However, a significant
effect was found in reducing the stress response
(cortisol) compared with using standard (hyperoxic) CPB
(Figure E2, Table E3).
The TnI levels peaked at 10 minutes after cessation of
CPB and started to decline from that point onward
(Figure E3, Table E3). No statistically significant difference
was found in the release of TnI between the controlled
reoxygenation and standard (hyperoxic) CPB groups
(P ¼ .31).
Controlled reoxygenation CPB significantly decreased
postoperative 8-isoprostane release compared with standard
(hyperoxic) CPB (ratio, 0.52; 95% CI, 0.47-0.60; P<.01).ery c September 2014
FIGURE 3. Time-related plasma changes in the geometric mean for interleukin (IL)-6, IL-10, IL-8, complement activation (C3a), macrophage migration
inhibitor factor (MIF), and cortisol in patients with a single ventricle in the standard (hyperoxic) (squares) and controlled reoxygenation (diamonds)
cardiopulmonary bypass (CPB) groups. Unit of concentration, ng/mL.
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group was significantly lower than in the standard
(hyperoxic) CPB group (ratio, 0.83; 95% CI, 0.74-0.93;
P < .01; Figure E3, Table E3). The a-glutathione
S-transferase level peaked significantly at 4 hours after
termination of CPB. Overall, a significant reduction was
seen in serum a-glutathione S-transferase release in the
controlled reoxygenation CPB group compared with the
standard (hyperoxic) CPB group (ratio, 0.87; 95% CI,
0.78-0.99; P<.01; Figure E3, Table E3).
DISCUSSION
The present study reports several novel findings
relating to the protection of cyanotic patients with a single
or double ventricle during corrective surgery. ControlledThe Journal of Thoracic and Careoxygenation (low PaO2, normoxic to patients) when
starting CPB in cyanotic patients with a single ventricle
reduced the markers of organ injury, systemic inflamma-
tion, and stress compared with standard reoxygenation
(physiologic PaO2, hyperoxic to patients). However, the
protective efficacy of this intervention was markedly
reduced in patients with a double ventricle. The mechanism
of action of controlled reoxygenation CPB in these cyanotic
patients is likely to be the gradual reintroduction of oxygen
into chronically hypoxic organs (eg, the heart5). However,
the main finding of our study was that controlled reoxyge-
nation is only effective at reducing the markers of inflam-
mation and cardiac injury in those with a single ventricle.
Although patients with a single or double ventricle are
cyanotic, key differences exist that can explain why thisrdiovascular Surgery c Volume 148, Number 3 797
FIGURE 4. Time-related plasma changes in the geometric mean for troponin I, 8-isoprostane, protein S100, and a-glutathione S-transferase in patients
with a single ventricle in the standard (hyperoxic) (squares) and controlled reoxygenation (diamonds) cardiopulmonary bypass (CPB) groups. Unit of
concentration, ng/mL. a-GT, a-Glutathione S-transferase.
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Cyanosis in single-ventricle patients remains at a relatively
constant level, rendering the heart (and other organs)
chronically hypoxic. In contrast, the degree of cyanosis in
patients with a double ventricle tends to be lower and to
fluctuate. It is likely, therefore, that single-ventricle
patients will sustain more reoxygenation injury when
receiving standard (hyperoxic) CPB. A greater degree of
organ reoxygenation injury in single-ventricle patients
will trigger relatively more oxidative stress and inflamma-
tory response.15
Controlled Reoxygenation and Biomarkers of
Inflammation and Oxidative Stress
Our suggestion that single-ventricle patients will sustain
significant reoxygenation injury is supported by a recent
study showing that immediately after CPB the levels of
markers of oxidative stress are increased16 and that
oxidative stress precedes the peak systemic inflammatory
response.17 The 8-isoprostane levels (oxidative stress)
will peak during CPB, and most inflammatory markers798 The Journal of Thoracic and Cardiovascular Surg(ILs and complement C3a) will hardly change during this
period (Figures 3 and 4, Figures E2 and E3). The C3a
levels were particularly high in single-ventricle patients
(Figure 3) and have been previously associated with
effusion and edema after CPB in pediatric patients.18,19
Single-ventricle anatomy is a key risk factor for operative
mortality.3 In contrast, the role of CPB-induced systemic
inflammatory response in postoperative morbidity appears
to be limited in infants undergoing low-to-moderate
complexity cardiac surgery.20
Despite the link between the inflammatory response and
postoperative complications, attempts at reducing this
response (eg, using steroids) during pediatric cardiac
surgery have not appeared to produce significant
effects on postoperative recovery.21 The identification of
other mediators of inflammation, including MIF, might
provide another strategy in the treatment of postoperative
inflammation in heart surgery patients.22-24 Work has
shown that oxidative stress induces secretion of MIF from
the cardiomyocytes themselves.25 Our data have strongly
indicated that increased circulating levels of MIF areery c September 2014
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(Figures 3 and 4). The finding that MIF was reduced by
controlled reoxygenation only in single-ventricle patients
is consistent with the intervention reducing cardiac injury
(Figures 3 and 4). Reducing the levels of MIF is
important, because reports have shown that it depresses
human myocardial contractile function and impairs
mitochondrial respiration.26 The same trend was not
observed in patients with a double ventricle, in whom
controlling reoxygenation did not significantly influence
the release of MIF and TnI.
Controlled Reoxygenation and Organ Injury
Surgical correction can trigger a significant systemic
inflammatory and stress response with the postoperative
increase of ILs, complement C3a, and cortisol. A devas-
tating consequence of the systemic inflammatory response
is the development of remote organ injury and multiorgan
dysfunction syndrome.27 This can lead to pulmonary,
hepatic, renal, gastrointestinal, myocardial, and cerebral
dysfunction.28 Several studies have shown a significant
positive correlation between the magnitude of the inflam-
matory response as measured by the serum concentrations
of IL-6 and IL-8 after CPB and the degree of medical
intervention after pediatric heart surgery, particularly in
patients with single-ventricle physiology.19 This group of
patients represents a particularly high-risk population in
terms of early- and long-term myocardial and cerebral
dysfunction. Therefore, strategies aimed at reducing the
intraoperative inflammatory and stress response with the
associated multiple organ damage arewarranted.1 However,
the relevance of these biomarkers in terms of clinical benefit
can only be established using a much larger sample size
with clinical primary endpoints. Our larger randomized
controlled trial, which has just completed recruitment of
220 patients, might provide some of the answers.
CONCLUSIONS
Our study has provided direct evidence that, in single-
ventricle patients, controlling reoxygenation will reduce
the blood markers of inflammation, stress, and markers of
myocardial, cerebral, and hepatic injury.
We would like to acknowledge Mrs Christine MacFadden for
helping with data collection and Mark Ginty for his technical
assistance.
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Dr David P. Bichell (Nashville, Tenn). Thank you for very
thought-provoking and well-presented data. Your group’s work
has helped frame the importance of hyperoxic injury from the
initiation of cardiopulmonary bypass, especially in cyanotic
infants, and now you very elegantly go further to show that the
injury is greatest for the single-ventricle cyanotic patients.
Other investigators have studied post-bypass hyperoxia-
induced stress injury and then have focused on pharmacologic
agents or other interventions to try to stamp out the fire already
lit by cardiopulmonary bypass and its inflammatory sequelae.
But your work points to a very appealing, practical, and more
preemptive approach of getting at the cause of it, and your
controlled reoxygenation strategy is appealing, especially
pertinent to the single-ventricle population, vulnerable in so
many ways and undergoing multiple insults on bypass, the
consequences of which compound.
I have a couple of questions.
The first is methodologic. In your 7-year follow-up data, the
single-ventricle patients, enrolled during the time of their Glenn
shunt, no doubt also underwent a Fontan procedure within the
study period. So that is 2 CPB runs. I just wonder how you treated
that with respect to the study design. In other words, if they were
randomized for hyperoxic versus controlled CPB at the first
operation, were those patients tracked and treated similarly at
the second insult of CPB? I am interested in how that fits in your
model and how that might affect the long-term data which, of
course, would then be influenced by multiple other factors.
Dr Caputo. If, for example, a patient undergoing a Glenn shunt
was randomized the first time, we could not recruit the same
patient for the total cavopulmonary connection. So when they
came to the Fontan, they were not randomized anymore. But we
did use the same strategy that was used for the first operation.
In a way, our study does really specifically consider the early
outcomes and biochemical markers of damage. Regarding the
follow-up, I do not think we have a significant number to have a
definite answer on the follow-up. So the outcomes of the follow-
up are more observational. We just wanted to present for the
completeness of the data, but we are not really saying that with
these numbers we randomized, we could have a definite answer
on the follow-up in terms of survival and ventricular function.800 The Journal of Thoracic and Cardiovascular SurgDr Bichell. It is an interesting striking difference in the
follow-up.
Dr Caputo. There is, yes.
Dr Bichell. It will be interesting to see more numbers for that.
Dr Caputo. Absolutely.
Dr Bichell. You divided your population into the single-
ventricle and biventricular patients, a heterogeneous mix of
each, and you nicely showed that a difference exists between the
2. Also, in the report, you speculated that the difference between
these 2 might be something to do with the chronicity and depth
of the cyanosis, with each respective group looking different,
and, therefore, the shock of hyperoxia looking different in 1 group
versus another.
But I wonder if there is not a more fundamental difference to
consider and perhaps consideration of dividing the groups
differently to be inclusive of the physiology that might drive
this. By that I mean, it is known that the lung is responsible for
an especially large portion of the reactivity of hyperoxic injury,
and it seems to me that the single-ventricle patients versus the
biventricular patients in general have parallel versus series
circulation. We are talking about an insult that occurs at the
initiation of CPB. In the parallel circulation patient, for example,
with shunt-dependent pulmonary blood flow, the initiation of
CPB results in distension of the pulmonary arterial tree with
hyperoxic blood, a shock, if you will, to the hypoxic initial state.
But for a septated, biventricular heart in series circulation, such
as a patient with tetralogy of Fallot, it is the opposite. The
pulmonary tree is actually emptied at the initiation of CPB.
Also, if there is hyperoxic injury, it is potentially more directed
to organs other than the lungs.
So I wonder if dividing the patients by series versus parallel
circulation, each group of which would contain some single and
some biventricular patients, you might further refine this effect
and/or explain it physiologically. That is a long way of asking,
have you considered this and were there patients in your study
who were, for example, a patient with tetralogy of Fallot with
major aortopulmonary collateral arteries who essentially had
systemic pulmonary circulation whose data can be analyzed to
see whether that is more of a physiologic explanation for the
difference you are seeing?
Dr Caputo. This is a really good suggestion. We have not
analyzed the data in that respect. Probably now that we have
finished the trial with>200 patients recruited, we should be able
to, because we might have enough numbers to subdivide into those
categories.
In this subgroup, some patients had a previous shunt and
possibly major aortopulmonary collateral arteries, but there were
not that many, so, again, to subdivide it into that group would
probably dilute the groups too much. But it is definitely something
that we should do with the larger cohort of patients.
In terms of why the single ventricle benefits more, several
explanations are possible. I think, as you suggested, there are
definitely patients with a double ventricle, such as, possibly, those
with transposition of the great arteries or very cyanotic tetralogy
with a Blalock-Taussig shunt, who could benefit as well. However,
perhaps, the ischemia reperfusion they undergo on top of the
oxygenation might have masked the effects of the benefits of the
oxygenation, because in single-ventricle patients, you either doery c September 2014
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probably the beneficial effect of controlling the reoxygenation is
not as evident in the biventricular repair where you do have to
crossclamp.
Dr Bichell.Well, this is very thought-provoking study and one
that I think can be integrated into a real practice change. I know I
had not before considered anything other than the dogmatic
approach of hyperoxic CPB, and you have given me pause to think
about this. I think this is an elegant method to connect data to a
change of practice.
Dr Caputo. Yes, thanks. Also, the good thing is that it is very
simple technique in a way, because it literally involves flushing
the CPB prime with nitric and it does not really affect the surgery,
the operation itself, so it is a quite simple technique.
DrMeena Nathan (Boston, MA).Are you planning to study the
neurologic outcomes of these patients? Do you have any early data
on that?
Dr Caputo. We just finished recruiting 230 patients, and we
followed them with Bayley’s and other neurocognitive tests for 6
months to 2 years, so I think the data will be available next
year, yes. That is our primary target, studying the neurologic
outcomes.
Dr Duke E. Cameron (Baltimore, Md). I enjoyed the study
very much as well. A quick question about your protocol. If I
read the slides right, on your controlled reoxygenation, you wereThe Journal of Thoracic and Cahypoxic at the institution of CPB but you allowed the oxygen
partial pressure to increase.
The reason I am asking this is that controlled reoxygenation
injury is worse in ischemic tissues than in those normally perfused,
and I am asking what was the oxygen partial pressure for these
patients just before the crossclamp was removed? Because I was
not clear of the rationale of lowering it when you institute CPB,
but letting it increase again and be hyperoxic just before
reperfusing the heart, which would be the organ most at risk of
this kind of injury.
Dr Caputo. That is a very good observation. We based our
strategy on our previous data. We analyzed the release of, for
example, troponin I in cyanotic patients, and it appeared that it
was the initial experience of the high oxygen during CPB that
created the damage. We saw as early as at 10 minutes of CPB,
an increase in the blood level of troponin I. So in the single
ventricle, most of these patients did not have the crossclamp, so
that was a very homogeneous group. That is why I think it was
the best possible group to study this entity. In the double ventricle,
I have not specifically concentrated on that. So, you are asking
what was the oxygen partial pressure when we crossclamp,
so before crossclamping?
Dr Cameron. Just before you came off.
Dr Caputo. We have not studied that. It is possibly a good
suggestion, and we should have the data to analyze.rdiovascular Surgery c Volume 148, Number 3 801
FIGURE E1. Survival at follow-up (median, 7 years) in (A) all patients and (B) patients with a single ventricle (SV) in the standard (hyperoxic) and
controlled reoxygenation groups. Cum, Cumulative; IQR, interquartile range.
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FIGUREE2. Time-related plasma changes in the geometric mean for interleukin (IL)-6, IL-10, IL-8, complement activation (C3a), macrophage migration
inhibitor factor (MIF), and cortisol in patients with a double ventricle in the standard (hyperoxic) (squares) and controlled reoxygenation (diamonds)
cardiopulmonary bypass (CPB) groups. Unit of concentration, ng/mL.
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FIGURE E3. Time-related plasma changes in the geometric mean for troponin I, 8-isoprostane, protein S100, and a-glutathione S-transferase in patients
with a double ventricle in the standard (hyperoxic) (squares) and controlled reoxygenation (diamonds) cardiopulmonary bypass (CPB) groups. Unit of
concentration, ng/mL.
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TABLE E1. Preoperative characteristics and intraoperative and postoperative data in cyanotic double-ventricle patients exposed to standard or
controlled reoxygenation
Variable Standard (n ¼ 23) Controlled reoxygenation (n ¼ 24) P value
Age (d) 223 (74-434) 217.5 (29-550) .8
Male sex 13 (56) 16 (66) .5
Weight (kg) 7.6 (4.7-9.8) 7.6 (3.6-9.3) .4
Preoperative saturation (%) 81.4  5.3 78.0  10.1 .2
Pathologic entity .1
Tetralogy of Fallot (complete repair) 16 (70) 15 (62)
TGA (arterial switch operation) 5 (22) 7 (29)
Other (aortic or mitral valve procedure) 2 (9) 2 (8)
PaO2
At start of CPB 165.0  61.1 51.7  13.2 <.001
At 5 min of CPB 231.4  60.1 66.0  46.1 <.001
At 10 min of CPB 216.2  56.7 79.0  43.5 <.001
At 30 min of CPB 184.2  34.0 116.3  28.8 <.001
Immediately after CPB 171.4  47.9 163.1  45.6 .6
CPB time (min) 105.4 (60-210) 92.6 (50-147) .9
Crossclamp time (min) 62.0  25.7 54.7  22.9 .1
30-d mortality 0 0
Ventilation time (min) 38.8 (18-287) 33.6 (6-191) .8
Dopamine support off CPB (mg/kg/min) 7.1  4.5 7.2  3.0 .9
Dopamine support peak dose (mg/kg/min) 10.1  4.3 12.3  4.6 .1
Dopamine support duration (h) 51.6  58.6 53.3  47.3 .9
Length of hospital stay (d) 7.0 (6.0-10.0) 7.5 (5.2-11.7) .3
Data presented as median (interquartile range), n (%), or mean standard deviation. TGA, Transposition of the great arteries; PaO2, partial pressure of oxygen in arterial blood;
CPB, cardiopulmonary bypass.
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TABLE E2. Biochemical marker release in patients with single-ventricle anatomy
Variable Measurement point
Geometric mean*
Ratio 95% CI P valueControlled reoxygenation Standard (hyperoxic)
Troponin I
Preoperatively
10 min on CPB 0.13 0.20 0.66
30 min on CPB 0.35 0.63 0.55
10 min off CPB 0.83 1.77 0.47
4 h after CPB 1.28 2.01 0.65
24 h after CPB 1.26 2.26 0.56
Test for interaction between treatment and time .465
Treatment effect, pooled over all points 0.58 0.51-0.65 <.01
8-Isoprostane
Preoperatively
10 min on CPB 6.10 8.19 0.74
30 min on CPB 8.61 9.47 0.91
10 min off CPB 7.30 8.38 0.87
4 h after CPB 5.33 6.59 0.81
24 h after CPB 2.50 4.77 0.52
Test for interaction between treatment and time .45
Treatment effect, pooled over all points 0.76 0.65-0.91 .002
IL-6
Preoperatively
10 min on CPB 0.82 1.57 0.51
30 min on CPB 1.70 1.66 1.02
10 min off CPB 6.40 14.53 0.45
4 h after CPB 27.73 51.26 0.54
24 h after CPB 34.63 35.21 0.98
Test for interaction between treatment and time .39
Treatment effect, pooled over all points 0.66 0.46-0.93 .02
IL-8
Preoperatively
10 min on CPB 6.36 8.28 0.76
30 min on CPB 7.21 8.56 0.85
10 min off CPB 13.57 16.24 0.83
4 h after CPB 35.07 38.42 0.91
24 h after CPB 15.96 21.67 0.72
Test for interaction between treatment and time .9
Treatment effect, pooled over all points 0.71 0.78-0.87 <.01
IL-10
Preoperatively
10 min on CPB 21.04 23.89 0.87
30 min on CPB 29.25 49.05 0.60
10 min off CPB 149.80 313.64 0.48
4 h after CPB 112.96 140.74 0.79
24 h after CPB 26.72 16.77 1.62
Test for interaction between treatment and time .1
Treatment effect, pooled over all points 0.78 0.58-1.05 .1
C3a
Preoperatively
10 min on CPB 1575.25 1674.40 0.95
30 min on CPB 1521.66 1961.73 0.79
10 min off CPB 1727.88 1923.11 0.91
4 h after CPB 1286.28 1545.58 0.83
24 h after CPB 1072.66 1181.17 0.91
Test for interaction between treatment and time .52
Treatment effect, pooled over all points 0.87 0.81-0.93 <.01
(Continued)
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TABLE E2. Continued
Variable Measurement point
Geometric mean*
Ratio 95% CI P valueControlled reoxygenation Standard (hyperoxic)
Cortisol
Preoperatively
10 min on CPB 227.01 212.75 1.07
30 min on CPB 214.15 228.80 0.93
10 min off CPB 223.34 276.39 0.81
4 h after CPB 396.57 484.54 0.81
24 h after CPB 664.05 770.05 0.85
Test for interaction between treatment and time .53
Treatment effect, pooled over all points 0.91 0.83-0.99 .04
S100
Preoperatively
10 min on CPB 304.91 445.95 0.68
30 min on CPB 579.07 615.59 0.93
10 min off CPB 756.09 1047.88 0.72
4 h after CPB 250.73 266.72 0.93
24 h after CPB 110.34 176.45 0.62
Test for interaction between treatment and time .1
Treatment effect, pooled over all points 0.78 0.66-0.91 .002
a-GT
Preoperatively
10 min on CPB 3223.37 4210.38 0.78
30 min on CPB 4362.86 5125.54 0.85
10 min off CPB 5338.99 6296.52 0.85
4 h after CPB 5935.48 9290.56 0.63
24 h after CPB 3423.88 6604.01 0.51
Test for interaction between treatment and time .52
Treatment effect, pooled over all points 0.71 0.60-0.85 <.01
MIF
Preoperatively
10 min on CPB 10.16 16.08 0.63
30 min on CPB 16.31 19.86 0.81
10 min off CPB 23.00 32.12 0.71
4 h after CPB 11.84 15.67 0.76
24 h after CPB 9.40 11.02 0.85
Test for interaction between treatment and time .44
Treatment effect, pooled over all points 0.74 0.69-0.79 <.01
CI, Confidence interval; CPB, cardiopulmonary bypass; IL, interleukin; C3a, complementary activation; a-GT, a-glutathione S-transferase;MIF, microphage migration inhibitor
factor. *Geometric mean values for measurement during and after surgery were adjusted for age, pathologic entity, preoperative values, and treatment.
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TABLE E3. Biochemical marker release in patients with double ventricular anatomy
Variable Measurement point
Geometric mean*
Ratio 95% CI P valueControlled reoxygenation Standard (hyperoxic)
Troponin I
Preoperatively
10 min on CPB 0.43 0.40 1.10
30 min on CPB 1.88 1.25 1.48
10 min off CPB 19.17 20.66 0.91
4 h after CPB 18.75 19.86 0.93
24 h after CPB 10.98 10.10 1.10
Test for interaction between treatment and time .7
Treatment effect, pooled over all points 1.1 0.93-1.29 .31
8-Isoprostane
Preoperatively
10 min on CPB 5.05 9.67 0.51
30 min on CPB 5.23 9.77 0.54
10 min off CPB 5.29 10.46 0.50
4 h after CPB 2.58 3.98 0.65
24 h after CPB 1.24 2.80 0.44
Test for common ratio .9
Treatment effect, pooled over all points 0.52 0.47-0.6 <.01
IL-6
Preoperatively
10 min on CPB 0.35 0.35 0.98
30 min on CPB 0.22 0.25 0.87
10 min off CPB 6.15 2.25 2.75
4 h after CPB 40.14 41.32 0.95
24 h after CPB 65.16 61.27 1.05
Test for interaction between treatment and time .46
Treatment effect, pooled over all points 1.15 0.87-1.48 .3
IL-8
Preoperatively
10 min on CPB 7.37 7.43 1.00
30 min on CPB 8.17 9.76 0.83
10 min off CPB 22.33 26.00 0.87
4 h after CPB 39.11 34.76 1.12
24 h after CPB 37.06 34.35 1.07
Test for interaction between treatment and time .29
Treatment effect, pooled over all points 0.98 0.87-1.1 .61
IL-10
Preoperatively
10 min on CPB 8.65 16.15 0.54
30 min on CPB 15.59 16.16 0.95
10 min off CPB 122.35 170.96 0.72
4 h after CPB 87.07 113.23 0.78
24 h after CPB 32.99 33.20 1.00
Test for interaction between treatment and time .6
Treatment effect, pooled over all points 0.79 0.66-0.95 .01
C3a
Preoperatively
10 min on CPB 1046.64 1024.24 1.02
30 min on CPB 1187.34 1219.30 0.95
10 min off CPB 1391.82 1708.55 0.81
4 h after CPB 1277.29 1221.53 1.05
24 h after CPB 925.24 943.06 1.00
Test for interaction between treatment and time .62
Treatment effect, pooled over all points 0.85 0.78-1.05 .38
(Continued)
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TABLE E3. Continued
Variable Measurement point
Geometric mean*
Ratio 95% CI P valueControlled reoxygenation Standard (hyperoxic)
Cortisol
Preoperatively
10 min on CPB 306.58 344.30 0.89
30 min on CPB 329.73 354.34 0.93
10 min off CPB 259.80 314.30 0.81
4 h after CPB 129.06 188.94 0.68
24 h after CPB 283.37 297.32 0.95
Test for interaction between treatment and time .68
Treatment effect, pooled over all points 0.85 0.78-0.93 <.01
S100
Preoperatively
10 min on CPB 382.20 490.88 0.78
30 min on CPB 721.49 807.65 0.89
10 min off CPB 1707.54 2293.36 0.74
4 h after CPB 370.17 346.07 1.07
24 h after CPB 174.64 242.67 0.71
Test for interaction between treatment and time .4
Treatment effect, pooled over all points 0.83 0.74-0.93 <.01
a-GT
Preoperatively
10 min on CPB 3240.35 4037.40 0.79
30 min on CPB 4066.82 4446.05 0.91
10 min off CPB 5815.27 8080.95 0.71
4 h after CPB 9091.89 8340.08 1.10
24 h after CPB 3627.80 3765.82 0.95
Test for interaction between treatment and time .4
Treatment effect, pooled over all time points 0.87 0.78-0.99 <.01
MIF
Preoperatively
10 min on CPB 12.97 14.63 0.87
30 min on CPB 19.77 19.86 1.00
10 min off CPB 48.69 49.26 1.00
4 h after CPB 15.01 18.51 0.81
24 h after CPB 11.00 10.98 1.00
Test for interaction between treatment and time .8
Treatment effect, pooled over all points 0.93 0.87-1.02 .11
CI, Confidence interval; CPB, cardiopulmonary bypass; IL, interleukin; C3a, complementary activation; a-GT, a-glutathione S-transferase;MIF, microphage migration inhibitor
factor. *Geometric mean values for measurement during and after surgery were adjusted for age, pathologic entity, preoperative values, and treatment.
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